NeuroMedix mails Directors' Circular



    TORONTO, April 4 /CNW/ - NeuroMedix Inc. ("NeuroMedix") (TSXV: NMX) today
announced that it has mailed its Directors' Circular in connection with the
tender offer made by Transition Therapeutics Inc. ("Transition") to acquire
all of the outstanding shares of NeuroMedix. Transition's Offering Circular
and related documents were mailed with the Director's Circular. Both the
Directors' Circular and Offering Circular can be found on SEDAR at
www.sedar.com.

    Terms and Conditions

    Transition has made a tender offer ("Offer") for all the outstanding
shares of NeuroMedix. Under the Offer, NeuroMedix common shareholders are
being offered one common share of Transition for every 5.1429 NeuroMedix
common shares tendered until the expiry of the Offer on May 9, 2007. The Offer
is subject to a minimum acceptance by the holders of at least 66 2/3% of all
the shares of NeuroMedix.
    The Board of Directors of NeuroMedix unanimously recommends that
NeuroMedix shareholders tender their shares to the Offer. NeuroMedix's
directors, officers and certain large shareholders who collectively own or
control 59% of the NeuroMedix shares have signed lock-up agreements in which
they agree to tender their shares to the Offer.

    About NeuroMedix:

    NeuroMedix is a biotechnology company focused on the development of
therapeutic agents for the treatment of degenerative and inflammatory diseases
of the central nervous system, such as Alzheimer's disease, traumatic brain
injury, neuropathic pain, age-related macular degeneration and multiple
sclerosis. Our therapeutic drug candidates are based on research from a team
of leading experts in the field of neuroinflammation at Northwestern
University and have been demonstrated to reduce brain inflammation, to protect
neuronal cells, and to prevent the loss of cognitive function in an
Alzheimer's disease animal model in mice. Our lead candidate, Minozac has also
been shown to reduce inflammation and prevent loss of cognitive function in
mice suffering traumatic brain injury. Based on these findings, NeuroMedix is
pursuing the development of its lead compound for Alzheimer's disease and
traumatic brain injury in humans. NeuroMedix's shares are listed on the TSX
Venture Exchange under the symbol "NMX".

    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this release.

    Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risks and
uncertainties, which may include but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

    %SEDAR: 00022976E




For further information:

For further information: www.neuromedixinc.com; Mark Pearson, PhD.,
Chief Executive Officer, NeuroMedix Inc., (425) 503-5156,
mark@neuromedixinc.com; Catherine Auld, CA, Chief Financial Officer,
NeuroMedix Inc., (416) 673-8190, cathy@neuromedixinc.com

Organization Profile

NEUROMEDIX INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890